AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05266456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 24 valent pneumococcal conjugate vaccine
Description: 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
Study NCT06265077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06265077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: famotidine and loratadine
Description: famotidine 20 mg once daily and loratadine 10 mg once daily
Study NCT05497440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: All'InCath CBC 035M Balloon Dilatation Catheter
Description: All participants will undergo the same intervention. Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography.
Study NCT05266456 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 20 valent pneumococcal conjugate vaccine
Description: 0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1
Study NCT06354244 — intervention group
Intervention type: DEVICE
Intervention: Electroacupuncture of 2 sessions per week
Description: Acupoints including bilateral BL23, BL32, BL33, BL35 and SP6 are inserted with acupuncture needles(size 0.30 × 40 mm and 0.30 × 75 mm or 0.40 × 100 mm,Hwato Brand). Bilateral BL32 and BL33 are needled to a depth of 70-95 mm with an angle of 60°-75° inward and downward, into the second and third sacral foramen. Bilateral BL35 are needled to a depth of 60-70 mm in a slightly superolateral direction. Bilateral BL23 and SP6 are vertically needled to a depth of 25-30 mm. After deqi is evoked, electric stimulators with a 5Hz continuous wave (5-10 mA intensity) are separately connected to bilateral BL32, BL33,BL35 and SP6. Current intensity is adjusted according to the patients' individual tolerance. During each session, electroacupuncture(EA) is retained for 30 minutes. The patients receive EA 2 sessions per week for 2-24 weeks.EA can be terminated if the patient acquire satisfactory spontaneous urination.
Study NCT06354244 — intervention group
Intervention type: DEVICE
Intervention: Electroacupuncture of 3 sessions per week
Description: Acupoints and electroacupuncture (EA) procedures are the same as in the group of EA of 2 sessions per week, but the patients receive EA 3 sessions per week for 2-24 weeks in this group.EA can be terminated if the patient acquire satisfactory spontaneous urination.
Study NCT06354244 — intervention group
Intervention type: DEVICE
Intervention: Electroacupuncture of 4 sessions per week
Description: Acupoints and electroacupuncture (EA) procedures are the same as in the group of EA of 2 sessions per week, but the patients receive EA 4 sessions per week for 2-24 weeks in this group.EA can be terminated if the patient acquire satisfactory spontaneous urination.
Study NCT06210412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health education and yoga intervention group
Description: Health education program based on the Penderin Health Promotion Model; It consists of 10 sessions as a program focused on the management of menopause (increasing the quality of life by teaching physical, psychological and social coping methods in menopause, yoga practices and their importance). In the first week, introduction, first tests (Sociodemographic data form, MÖYKÖ), and general introduction of the program will be made. It is a program in which active education methods (question and answer, role play, demonstration, etc.) are used, with each session planned to last approximately 30 minutes. Final tests will be performed at the end of 12 weeks.~Yoga practice will be carried out as 45-minute sessions 2 days a week, which will last for 12 weeks, following the health education program.12. At the end of the week, MOQÖ and Yoga Transformation Impact Scale will be applied to those who have completed 10 weeks.
Study NCT06463964 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Creatinine
Description: Laborataries for prediction of AKi in patients with ADHF
Study NCT05895084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Yoga
Description: Yoga is delivered as described in an earlier section in a group format. Classes are an hour in duration and occur once per week for 8 weeks, and they are led by an adaptive yoga specialist.
Study NCT04605562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP+DDP
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles; induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
Study NCT04605562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Administered orally
Study NCT04605562 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
Study NCT04605562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody
Description: Administered every 3 weeks
Study NCT04605562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally
Study NCT04790240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inflammation (I)
Description: 1. upper respiratory inflammation (PurInf (I)): Lonicerae Flos 2.4g, Forsythiae Fructus 2.4g, Schizonepetae Herba 2g, Saposhnikoviae Radix 2g, Cicadae Periostracum 1g, Sophorae flavescentis Radix 2.4g, Atractylodis Rhizoma 2g, Angelicae dahuricae Radix 2g, Menthae haplocalycis Herba 2g, Arctii Fructus 2g, Glycyrrhizae Radix 1g~2. high fever (PurInf (II)): Bupleuri Radix 3g, Scutellariae Radix 2.4g, Gypsum fibrosum 4g, Anemarrhenae Rhizoma 3g~3. lower Respiratory system inflammation (PurInf (III)): Scutellariae Radix 2.4g, Coptidis Rhizoma 1g, Phellodendri Cortex 2.4g, Gardeniae Fructus 2.4g, Houttuyniae Herba 4g, Golden Buckwheat 3g
Study NCT04790240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inflammation (II)
Description: Platycodi Radix 2.4g, Peucedani Radix 2.4g, Cynanchi stauntonii Rhizoma 2.4g, Asteris Radix 2.4g, Stemonae Radix 2.4g, Lepidii Descurainiae Semen 2.4g, Plantaginis Semen 2.4g
Study NCT04790240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inflammation (III)
Description: 1. Metabolites, abnormal fluids (PurPhl):~   Citri reticulatae Pericarpium 1.2g, Citri grandis Exocartium rubrum 2g, Aurantii Fructus immaturu 2g, Pinelliae Rhizoma preparatum 2.4g, Arisaematis Rhizoma preparatum 2.4g, Amoni Fructus 1g, Trichosanthis Fructus 2.4g, Fritillatiae cirrhosae Bulbu 2.4g, Poria 2.4g, Rhei Radix et Rhizoma 1g~2. Capillaries circulation disorder (PurClo):~Salviae miltiorrhizae Radix 2.4g, Curcumae Radix 2.4g, Paeoniae Radix rubra 2.4g, Persicae Semen 2.4g, Carthami Flos 2.4g
Study NCT04790240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: remdesivir (Veklury), Colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab \& Imdevimab.
Study NCT04504487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drain Removal
Description: Abdominal drain placed during surgery removal
Study NCT04504487 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Drain Removal
Description: Abdominal drain placed during surgery removal
Study NCT05099926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing Exercise Sensitivity with Exposure Training
Description: Participants complete 2, home-based intervention visits on a secure video visit platform. Video visits include psychoeducation, interoceptive exposure, and interoceptive counseling. For homework, participants are asked to document their weekly physical activity and exercise sensations in a journal.~Psychoeducation: Participants are educated about the benefits and safety of exercise and cardiac rehabilitation, the role of fear and anxiety in exercise avoidance, and the concept of interoceptive exposure.~Interoceptive Exposure: A gradual six-minute walk (G6MW) serves as a low-risk form of interoceptive exposure. Exercise sensations and ratings of perceived intensity and distress are collected before and after the G6MW.~Interoceptive Counseling: Participants review and reflect upon their pre-walking and post-walking physical sensations and ratings (intensity and distress) with a research team member. Homework is also reviewed.
Study NCT05858385 — intervention group
Intervention type: OTHER
Intervention: Intervention based on key factors identified by the severe RIOM prediction model
Description: Intervention based on key factors identified by the severe RIOM prediction model
Study NCT05334654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Sodium
Description: Enoxaparin will be subcutaneously administered at a dosage from 4000 to 8000 twice daily according
Study NCT05334654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Bivalirudin will be intravenously administered to obtain an activated prothrombin time (aPTT) of 1.5 fold of the normal values.
Study NCT05965193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normobaric Hyperoxia
Description: Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
Study NCT05965193 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal oxygen
Description: For nasal oxygen group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.
Study NCT05965193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous thrombolysis(rt-PA)
Description: 10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
Study NCT05965193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis(rt-PA)
Description: 10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
Study NCT05043532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2 passes during EUS-guided fine needle biopsy
Description: Once the pancreatic mass has been visualized on endoscopic ultrasound, a total of two passes will be performed and placed in 10% formalin for processing for molecular profiling. Onsite evaluation will be performed using a part of the sample from the first pass in order to establish onsite diagnostic adequacy in all patients.
Study NCT05043532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3 passes during EUS-guided fine needle biopsy
Description: Once the pancreatic mass has been visualized on endoscopic ultrasound, a total of three passes will be performed and placed in 10% formalin for processing for molecular profiling. Onsite evaluation will be performed using a part of the sample from the first pass in order to establish onsite diagnostic adequacy in all patients.
Study NCT04940754 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: osteosynthesis
Description: Closed reduction, internal fixation
Study NCT06340841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Incentives
Description: The participant receives incentives directly if they complete an activity on a given day.
Study NCT06340841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Restorative Incentives
Description: The participant receives incentives directly if they complete an activity on a given day. They are given an additional incentive to return to completing activities if they did not complete an activity on a prior day.
Study NCT06340841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charity Incentives
Description: The participant earns compensation for charity if they complete an activity on a given day.
Study NCT06340841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charity Restorative Incentives
Description: The participant earns compensation for charity if they complete an activity on a given day. They are given an additional incentive for charity to return to completing activities if they did not complete an activity on a prior day.
Study NCT05198063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant novel coronavirus vaccine (CHO cells)
Description: At 6 months after the basic immunization (window period ± 1 month), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
Study NCT05091541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
Description: CT120 is an autologous CD19/22 targeted CAR-T cells injection. The dosage form is a cryopreserved injection solution. The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
Study NCT06445803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）
Description: CD19/CD22 cells will be infused on Day1 after induction chemotherapy regimen.~Lymphodepleting chemotherapy:3 days of IV chemotherapy with fludarabine and cyclophosphamide.~Fludarabine 30 mg/m2/day IV x 4 days (days -5 through -3) Cyclophosphamide 500 mg/m2/day IV x 2 days (days -5 and-3)
Study NCT05207657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lentiviral vector transduced CD34+ cells
Description: Gene therapy for p47 AR-CGD will be performed by introduction a normal copy of the NCF-1 gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient
Study NCT05537818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVPI Device
Description: The AVPI device system consists of a small, hand-held, micro-pressure pulse generator device that is operated by a hand-held mobile smartphone (iPhone®) with a downloaded software application or app. The AVPI device is connected to an earpiece assembly that splits into two earbuds (right and left) that seat comfortably into each respective ear.~1. AVPI device for pressure regulation~2. Earpiece Assembly - a small, flexible, hollow tube that divides into right and left earpieces~3. Earbuds - replaceable, multiple sizes~4. Smartphone with the AVPI app
Study NCT05537818 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AVPI Device
Description: The AVPI device system consists of a small, hand-held, micro-pressure pulse generator device that is operated by a hand-held mobile smartphone (iPhone®) with a downloaded software application or app. The AVPI device is connected to an earpiece assembly that splits into two earbuds (right and left) that seat comfortably into each respective ear.~1. AVPI device for pressure regulation~2. Earpiece Assembly - a small, flexible, hollow tube that divides into right and left earpieces~3. Earbuds - replaceable, multiple sizes~4. Smartphone with the AVPI app
Study NCT04758468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based pelvic floor muscle training
Description: Telerehabilitation-based pelvic floor muscle training group will individually receive telerehabilitation-based pelvic floor muscle training under the guidance of a physiotherapist 2 sessions per week for 8 weeks. Participants will do their exercises themselves 2 times on the days where sessions are held with a physiotherapist. Participants will continue to exercise 3 times a day in the remaining days.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks.
Study NCT04758468 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based pelvic floor muscle training
Description: The home-based pelvic floor muscle training group will do their individual exercises 3 times a day for 8 weeks.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks.
Study NCT04688242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anal dilatation per anus
Description: Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus
Study NCT04688242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of probiotics (Clostridium butyricum TO-A; Bacillus mesentericus TO-A; Streptococcus faecalisT-110) per anus
Description: Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus
Study NCT05970627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Perioperative Toripalimab, 240 mg IV infusion
Study NCT05970627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
Study NCT05970627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 orally intake as perioperative chemotherapy
Study NCT04762381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate
Description: 24 mg dexamethasone infused peroperatively
Study NCT04762381 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT05072873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Description: temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
Study NCT05072873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
Study NCT05089617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~Drug: Placebo~Placebo is the same appearance as YG1699.
Study NCT05117138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMT-116 CAR-T cells
Description: 1. Classical 3+3 dose escalation will be applied to 9 subjects with moderate or far advanced non-small cell lung carcinoma (NSCLC) enrolled.~2. Classical 3+3 dose escalation will be applied to 9 subjects with moderate or far advanced head and neck Squamous Cell Carcinoma (HNSCC) enrolled.
Study NCT05117138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMT-253 CAR-T cells
Description: 1.The classic 3 + 3 dose escalation will be applied to 9 selected subjects with moderate or far advanced melanoma by intravenous drip.~2.3 \~ 6 patients with intermediate and advanced melanoma will be injected intratumorally at a dose of ≤ 1 × 10\^8 cells.~3.3 \~ 6 patients with operable advanced melanoma will be treated with postoperative adjuvant treatment at a dose of ≤ 1 × 10\^8 cells ≤ intravenous drip on Day 1 of each 42 days cycle (8 cycle maximum).
Study NCT04901650 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Survey
Description: A survey will be administered to find out the prevalence of pain in hospitalized patients for any cause and its intensity. The medical history will be reviewed to assess the presence of pain medications and their impact on the pain perception and patients' satisfaction.
Study NCT05102279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Giving subjects different phosphorus diets at different stages of the trial
Description: Ordinary phosphorus diet: Phosphorus content 1500mg High phosphorus diet: Phosphorus content 2500mg (inorganic phosphorus is added to the ordinary phosphorus diet) Low phosphorus diet: Phosphorus content 500mg (Protein content is achieved through chicken albumen and addition of low-phosphorus whey protein powder) The ratio of plant protein and animal protein is the same as the other two diets. In addition, calcium-magnesium tablets and potassium chloride salt are added to achieve the same calcium, magnesium and potassium content as the other two diets.) There are 2 recipes for each diet. Ensure that the energy, protein, fat, carbohydrate, calcium, magnesium, sodium, potassium, oxalic acid content, vegetable protein and animal protein ratio are basically the same: Energy: 2100kcal (30kcal/kg, standard body weight 70kg) Protein: 110g Fat: 55-60g Carbohydrate: 300g Calcium: 600-700mg Magnesium: 350-400mg Sodium: 4600mg Potassium: 2500mg
Study NCT05102279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Giving subjects different phosphorus diets at different stages of the trial
Description: Ordinary phosphorus diet: Phosphorus content 1500mg High phosphorus diet: Phosphorus content 2500mg (inorganic phosphorus is added to the ordinary phosphorus diet) Low phosphorus diet: Phosphorus content 500mg (Protein content is achieved through chicken albumen and addition of low-phosphorus whey protein powder) The ratio of plant protein and animal protein is the same as the other two diets. In addition, calcium-magnesium tablets and potassium chloride salt are added to achieve the same calcium, magnesium and potassium content as the other two diets.) There are 2 recipes for each diet. Ensure that the energy, protein, fat, carbohydrate, calcium, magnesium, sodium, potassium, oxalic acid content, vegetable protein and animal protein ratio are basically the same: Energy: 2100kcal (30kcal/kg, standard body weight 70kg) Protein: 110g Fat: 55-60g Carbohydrate: 300g Calcium: 600-700mg Magnesium: 350-400mg Sodium: 4600mg Potassium: 2500mg